Effect of Suicidality on Social Cognition
Effect of Suicidality in Major Depressive Disorder During Social Cognition
1 other identifier
observational
150
1 country
1
Brief Summary
Major Depressive Disorder (MDD) is a very common illness that is usually treated with antidepressant medication. Depression can be caused by many things such as childhood experiences, genetics, and changes in the way the body and brain function. It is most likely caused by a combination of several of these factors. The prevalence of suicide attempt in Major Depressive Disorder (MDD) is about 20%. Risk for suicide attempt can be increased by many things such as negative life events, genetics, and changes in the way the body and brain function. It is most likely caused by a combination of several of these factors. In this study, the investigators will be collecting detailed information about participants' psychiatric history and depression symptoms, as well as brain scans. The goal is to use this information to help us determine what predicts suicide attempt history.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Sep 2022
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2022
CompletedFirst Submitted
Initial submission to the registry
November 22, 2023
CompletedFirst Posted
Study publicly available on registry
December 11, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2024
CompletedMay 9, 2024
May 1, 2024
2.3 years
November 22, 2023
May 7, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
fMRI Markers for Suicide Risk
Potential fMRI brain activity for suicide risk using participants' brain scans
Through study completion, an average of 1 week
Study Arms (3)
Healthy controls, or people who do not have depression.
People diagnosed with MDD and a history of suicide attempt
People diagnosed with MDD without a history of suicide attempt
Interventions
A study team member will meet the participant to ask questions regarding the degree of depression at the beginning of the study. This interview will take approximately 1 hour.
A study team member will ask the participant to complete questionnaires assessing the severity of the participant's depression, daily activities, personality/traits, and quality of life. If the participant opts to complete these questionnaires at home, they will be emailed them within 24 hours of this visit. These questionnaires will take approximately 1-2 hours.
The participant will be asked to undergo a magnetic resonance imaging (MRI) scan to look at the structure and function of their brain. The functional MRI measures the level of blood flow to areas of the brain associated with mood and behaviour, and the participant will be asked to complete two behavioural games while they are in the scanner. During the scan, the participant will be required to lie on a table within the cylindrical tube of the MRI scanner in order to complete the scan. This will result in limited movement for the duration of the scan. The scan will take approximately 60 minutes.
The participant will be asked to complete two behavioural games inside the scanner. One of these games includes a monetary payout. They will be given instructions about these tasks outside of the scanner.
Eligibility Criteria
People will be assessed for a major depressive episode and history of suicide attempt. There will be three samples enrolled in this study: * Group 1: 50 healthy controls, or people who do not have depression. * Group 2: 50 people diagnosed with MDD and a history of suicide attempt * Group 3: 50 people diagnosed with MDD without a history of suicide attempt.
You may qualify if:
- Depressed Participants:
- Between the ages of 18 and 65 years old.
- Capable of giving voluntary and informed consent.
- Fluent in English.
- Meet DSM-5 criteria for single or recurrent Major Depressive Disorder (current major depressive episode), confirmed via the Mini-International Neuropsychiatric Interview (MINI 6.086).
- Moderate to severe depression severity, defined as a 17-item Hamilton Depression Rating Scale87 score ≥ 17.
- Have had no initiation or dose change in any psychotropic medication in the four weeks prior to screening, as confirmed by the Antidepressant Treatment History Form (ATHF88).
- If participating in psychotherapy, must have been in stable treatment for at least 3 months prior to entry into the study, with no anticipation of change in the frequency of therapeutic sessions, or the therapeutic focus over the duration of the study.
- Can adhere to the study schedule.
- Either a history of or no lifetime history of suicide attempt, confirmed via the Mini-International Neuropsychiatric Interview (MINI 6.086).
- Nondepressed Participants:
- Between the ages of 18 and 65 years old.
- Capable of giving voluntary and informed consent.
- Fluent in English.
- No current or lifetime history of psychiatric diagnoses or suicidality, confirmed via the MINI 6.086.
- +2 more criteria
You may not qualify if:
- All Participants:
- Are pregnant/lactating.
- A MINI-confirmed diagnosis of major depressive disorder in people with bipolar disorder.
- Other major medical comorbidities requiring immediate investigation or treatment, cardiac pacemaker, or implanted medication pump.
- Lifetime history of psychosis, confirmed by the MINI 6.086, including schizophrenia, schizoaffective disorder, delusional disorder, or current psychotic symptoms.
- Drug abuse or dependence within the last 6 months, excluding caffeine and nicotine.
- Presence of contraindications for MRI, including metallic implants.
- Have any significant neurological disorder or insult including, but not limited to: any condition likely to be associated with increased intracranial pressure, space occupying brain lesion, any history of seizure except those therapeutically induced by ECT, cerebral aneurysm, Parkinson's disease, Huntington's chorea, multiple sclerosis, dementia, significant head trauma with loss of consciousness for greater than or equal to 5 minutes.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Unity Health Toronto
Toronto, Ontario, M5B1M8, Canada
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Katharine Dunlop, PhD
Unity Health Toronto
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 22, 2023
First Posted
December 11, 2023
Study Start
September 1, 2022
Primary Completion
December 31, 2024
Study Completion
December 31, 2024
Last Updated
May 9, 2024
Record last verified: 2024-05